US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

Sage Therapeutics, Inc. - Common Stock (NQ:SAGE)

8.680 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sage Therapeutics, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
What 5 Analyst Ratings Have To Say About Sage Therapeutics ↗
 
Via Benzinga
News headline image
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Present at the Cowen 43rd Annual Health Care Conference
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics Announces European Medicines Agency Granted SAGE-718 Orphan Drug Designation for the Treatment of Huntington’s Disease
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Scheduled For February 16, 2023 ↗
Companies Reporting Before The Bell • RELX (NYSE:RELX) is estimated to report earnings for its Fiscal Year 2022. • Coca-Cola Europacific (NASDAQ:CCEP) is expected to report earnings for its Fiscal Year... 
Via Benzinga
Expert Ratings for Sage Therapeutics ↗
 
Via Benzinga
Sage Therapeutics's Return On Capital Employed Insights ↗
 
Via Benzinga
News headline image
Sage Therapeutics/Biogen Highlight Additional Data From Depression Candidate ↗
 
Via Benzinga
News headline image
Sage Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics-Biogen Partnered Depression Candidate Under Priority FDA Review, Analyst Says Its 'Incrementally Positive' ↗
 
Via Benzinga
News headline image
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Biogen Inc.
Via GlobeNewswire
News headline image
Sage Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Provide Update on 2023 Key Initiatives at 41st Annual J.P. Morgan Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates
EQNX::TICKER_START (NASDAQ:SAGE),NASDAQ:NERV),(NASDAQ:ATAI),(NYSE:CYBN),(TSXV:MRVL),(NEO:CYBN), EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Retirement
News headline image
Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics Announces Third Quarter 2022 Financial Results and Highlights Pipeline and Business Progress
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
From Sage Therapeutics
Via Business Wire
News headline image
Sage Therapeutics to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Sage Therapeutics and Biogen Present Further Analyses from Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression at the European College of Neuropsychopharmacology (ECNP) Congress
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Mental Health Claims up 75% Since 2019
Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75% from 2019 as more Canadians tapped into their mental health benefits. According to the Canadian... 
Via PressReach
Mental Health Claims up 75% Since 2019
FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – September 23, 2022 – Canadian health insurers processed nearly $600 million in mental health service claims in 2021, up 75%... 
Via FinancialNewsMedia
News headline image
Sage Therapeutics and Biogen Present New Analyses at Psych Congress Further Evaluating the Efficacy and Safety of Zuranolone
From Sage Therapeutics, Inc.
Via Business Wire
News headline image
Sage Therapeutics Stock Scores Relative Strength Rating Upgrade ↗
On Friday, Sage Therapeutics stock received a positive adjustment to its Relative Strength (RS) Rating, from 86 to 91. 
Via Investor's Business Daily
News headline image
Sage Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
From Sage Therapeutics, Inc.
Via Business Wire
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >